Marquee Background
Marquee Background

Offit Kurman Blogs

Healthcare

Adaptogens and FDA/FTC Compliance

March 1, 2022

By Michael H. Cohen

Adaptogens ingredients refer to supplements and herbs that are used in the practice of alternative medicine. The makers and sellers of products with adaptogen ingredients claim that the ingredients have properties that help to strengthen and normalize a person’s bodily functions. According to Michigan State University, adaptogenic ingredients can be found in “traditional Ayurveda and Chinese medicine and other holistic herbal alternative medicine practices.”

According to the European Medicines Agency, adaptogen ingredients must include:

  • An almost non-toxic response in the recipient.
  • Non-specific pharmacological properties that increase an organism’s resistance to a broad spectrum of adverse biological, chemical, and physical factors.
  • The ability to be a regulator by having a normalizing effect on an organism’s various organ systems or other profound pathologic changes in the organism.

According to the Washington Post, consuming adaptogenic drinks in moderation has a low risk. Still, consumers need reliable advertising and marketing claims. The Post article states that adaptogens are a “broad class of herbs, botanicals, and mushrooms that have been associated with enticing effects — including relieving stress and improving mood — that are sometimes linked to the experience of drinking alcohol.” Adaptogens are being marketed as an alternative to alcohol. Nonalcoholic beverages promise some of the same reduced stress effects as alcohol drinks. Some nonalcoholic beverages from companies such as Kin Euphorics, Curious Elixirs, and Rasasvada include adaptogens.

There isn’t any current research or scientific evidence that currently supports the efficacy of adaptogen ingredients. The ingredients do not qualify as drugs, according to the FDA definition of drugs because they do not “treat, cure, or prevent any known ailments or diseases.” FDA does review any claims by a manufacturer or seller that the adaptogen ingredients act as drugs. If a company markets products as drugs, the company will likely be sent a warning letter to cease any such claims on the grounds that the products are adulterated and misbranded.

Adaptogens are considered dietary supplements. FDA has oversight over dietary supplements and dietary ingredients. Generally, FDA is limited in its ability to regulate supplements, according to Michigan State University, before the supplements are available for sale. While the manufacturers are responsible for the ingredients, FDA generally cannot recall the supplements until a sale has taken place and a consumer has filed a complaint.

IS YOUR PRODUCT A DIETARY SUPPLEMENT OR AN FDA-REGULATED DRUG? (PART 2)

In today’s video, we’ll talk about some more not so obvious ways that FDA can classify your dietary supplement as a drug.


What ingredients are common in adaptogens?

According to MSU, some common adaptogen ingredients include “Ashwagandha, Astragalus root, Bacopa Monnieri, cordyceps, Eleuthera, holy basil, licorice, maca, maitake, Rhodiola rosea (Arctic root), reishi, schizandra, shiitake, Siberian ginseng, and wild yam.”

Common adaptogen claims

Some of the statements that nonalcoholic drink companies make are:

  • Kin Euphorics website says “BYE BYE BOOZE. HELLO COSMIC WONDER,” and advertises that its drinks have “mood-boosting” or “mind-calming” ingredients.
  • Curious Elixirs describes its offerings as “complex booze-free cocktails infused with adaptogens to help you unwind.”

Adam Perlman, a physician and integrative and functional medicine specialist at the Mayo Clinic says that. “Very often there is some science to back these claims, but the science is often not as definitive as we’d like it to be.”

Mikhail Kogan, a geriatrician and medical director of the Center for Integrative Medicine at George Washington University says that adaptogens refers to a natural substance that “somehow protects against negative impacts of stress.” “Kogan said he uses tinctures of adaptogens himself, including schisandra, ginseng and rhodiola, and has recommended them to patients.”

Norbert Kaminski, a professor of pharmacology and toxicology and director of the Center for Research on Ingredient Safety at Michigan State University says, “The idea is these adaptogens help maintain your body and equilibrium.”

While the functions associated with the ingredients largely match the advertising language for nonalcoholic adaptogenic drinks, the claims are often vague. Kaminski said. “The things that they supposedly do often are very difficult to measure. You can’t quantify a lot of this.”

Adaptogenic products such as herbs, plants, and mushrooms do have a history of healing abilities – “But while some scientific evidence suggests there are benefits to consuming adaptogens, experts said much of the research involved animal studies, and that the few human trials were limited by small sample sizes.”

Do adaptogens actually meet the claims that these products reduce stress and balance systems? Adaptogen warning letters.

The FTC also has oversight over false claims makers and sellers of adaptogen ingredients make. The FTC regulates how a manufacturer or sell can advertise and market its dietary supplements. Claims must be truthful and substantiated. Claims cannot be misleading. FTC can send warning letters to the manufacturers and retailers of the dietary supplements if the agency believes the supplements are harmful or if the claim about their efficacy is improper.

For example, claims that adaptogen ingredients can cure, prevent, or mitigate COVID-19 symptoms will be met with FDA and FTC warning letters.

benjaminmcevoy.com – 607149 – 05/14/2020 | FDA.

FDA and FTC filed a joint warning letter against Benjamincovey.com claiming that the respondent sold products, including dietary supplements, through Amazon and promoted the products on the company website. The website includes claims “representing or implying that the products can mitigate, prevent, treat, diagnose, or cure COVID-19[2] in people.”

The warning letter asserted that these claims cause the products to be classified as unapproved new drugs under section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. § 355(a). The warning letters also stated that the products are misbranded drugs under section 502 of the FD&C Act, 21 U.S.C. § 352. Further, the warning letters said that the introduction or delivery of these products into interstate commerce violated the FD&C Act and that it was illegal under the FD&C Act “to do any act with respect to a drug, if such act is done while the drug is held for sale after shipment in interstate commerce and results in the drug being misbranded.”

Some of the claims that the warning letter said were improper included:

“Ashwaghanda [Amazon associate link] . . . Ashwaghanda is an adaptogen . . . which has many studied but yet to be understood positive effects on the immune system. Adaptogens reduce cortisol levels and improve immune response . . . You can learn more and buy ashwaghanda here [Amazon associate link].”

The respondent was given a deadline to respond to the warning letter or face further action.

A warning letter was filed against Red Moon Herbs.

The warning letter was filed by FDA and the FTC. The letter stated that agencies reviewed the company’s website and social media accounts. The agencies found that the company sold numerous products that “are intended to mitigate, prevent, treat, diagnose, or cure COVID-191 in people.” The warnings made similar assertions to the previous warning letter (Benjamincovey.com) that the products are new drugs and are thus adulterated, misbranded, and violate various provisions of the FD&C Act.

Included among the postings was the statement:

“Immunomodulating herbs – my top go-tos which are showing up again and again in the building literature surrounding this pandemic are astragalus, any and all medicinal mushrooms (reishi, turkey tail, chaga, lion’s mane, and Mushroom Elixir are favorites), and adaptogens including ashwagandha and ginseng. Echinacea and usnea are both effective immune stimulants and usnea have an affinity for the lungs which may prove relevant here. Astragalus and reishi are particularly gentle and good for all ages and my three year old takes them daily.”

The respondent was also given a deadly to reply or face further legal action.

Claims about adaptogen products

FDA and dietary supplements

FDA regulates finished dietary supplement products and dietary ingredients. The FDA regulates dietary supplements differently than drugs or food.

Under the Dietary Supplement Health and Education Act of 1994 (DSHEA):

Manufacturers and distributors of dietary supplements and dietary ingredients are prohibited from marketing products that are adulterated or misbranded.  That means that these firms are responsible for evaluating the safety and labeling of their products before marketing to ensure that the products meet all the requirements of DSHEA and FDA regulations.

FDA has the authority to take action (usually beginning with warning letters) “against any adulterated or misbranded dietary supplement product after it reaches the market.”

According to the FDA, “FDA’s Center for Food Safety and Applied Nutrition (CFSAN) is responsible for the agency’s oversight of these products. The Dietary Supplement Health and Education Act (DSHEA) of 1994, which amended the Federal Food, Drug, and Cosmetic Act, created a new regulatory framework for the safety and labeling of dietary supplements. FDA is not authorized to review dietary supplement products for safety and effectiveness before they are marketed.”

FDA and new dietary supplement regulation

According to former FDA Commissioner Scott Gottlieb, M.D., ¾ths of Americans take a dietary supplement on a regular basis. 4/5ths of seniors take a dietary supplement. Based on those large numbers, FDA announced new goals for dietary supplement regulation. Since the Dietary Supplement Health and Education Act (DHSEA) was passed more than 25 years ago, the dietary supplement industry has grown from $4 billion to $40 billion and from about 4,000 products to at least 50,000 products. While most manufacturers and sellers are responsible, the number of companies “marketing potentially dangerous products or making unproven or misleading claims about the health benefits they may deliver” has increased.

These proposed new goals apply to all dietary supplements including adaptogens.

Commissioner Gottlieb stated for the FDA:

  • The first priority is ensuring safety – that the products don’t cause harm.
  • The second priority is “product integrity: we want to ensure that dietary supplements contain the ingredients that they’re labeled to contain, and nothing else, and that those products are consistently manufactured according to quality standards. “
  • The third priority is “informed decision-making. We want to foster an environment where consumers and health care professionals are able to make informed decisions before recommending, purchasing or using dietary supplements.”

This last priority gets to another reason why it’s important to speak with an experienced healthcare lawyer. Skilled healthcare lawyers advise both the manufacturers and sellers of dietary supplements such as adaptogens and the physicians who recommend these supplements about their FDA compliance requirements.

The key steps Commissioner Gottlieb announced (that logically apply to adaptogens) are:

  • Better communication when there are concerns an ingredient is illegal, potentially dangerous, and shouldn’t be marketed as dietary supplements – including faster notifications about a product’s concerns to the public.
  • Flexibility in evaluating product safety while promoting innovation -including “steps to foster the submission of new dietary ingredient (NDI) notifications.”
  • “Working closely with our partners in industry to achieve our primary goal of protecting public health and safety. As the dietary supplement industry develops new products and ingredients, advances new delivery systems and innovates in other ways, the FDA must do more to leverage its existing resources and authorities to evaluate these products.” One step is the creation of the Botanical Safety Consortium, “a public-private partnership that will gather leading scientific minds from industry, academia and government to promote scientific advances in evaluating the safety of botanical ingredients and mixtures in dietary supplements.”
  • Developing new enforcement strategies including sending warning letters, and continuing compliance and “enforcement efforts against firms that have shown persistent inability to comply with the current good manufacturing practice requirements for dietary supplements, and taking action to protect the public against unsafe imports and recalled products.”

Many companies are making and selling products with herbs and other adaptogens that claim to relieve stress. These companies and any doctors who recommend adaptogens to their patients need to understand the FDA regulations that regulate drugs and dietary supplements. Skilled healthcare lawyers help clients take proactive steps to reduce the risk of FDA or FTC complaints and responsive steps if a company or doctor receives an FDA or FTC warning letter.

Our experienced healthcare attorneys help physicians and health companies understand their compliance requirements.

Categories: Healthcare

Related People

Related Services

  • Posts
  • About
  • Subscribe

Firm Highlights

  • Events
    AIA Tri-State Conference
    Princeton will serve as the backdrop for three days of connection, learning, and design leadership. From keynotes to tours to the Tri-State Design Awards, this year’s conference is designed to go far beyond education sessions. Kick off the week with pre-conference intensives and individual state component Design Award celebrations, followed by three days of education, inspiration, networking, and design excellence at the 2026 AIA Tri-State Conference—featuring pre-conference intensives, three keynote speakers, 25 education sessions, curated tours, an expo, spec academies, and the AIA Tri-State Design Awards—bringing together architects and design professionals from New Jersey, New York, and Pennsylvania to connect, learn, and celebrate the best of the profession. G2. Designing Secure Practices: Cybersecurity, Data Privacy, Contractual Provisions, and Insurance Risks for Architects (4:00 PM - 5:30 PM) Architects and design professionals increasingly rely on cloud platforms, BIM software, and digital tools to manage sensitive data, creating cybersecurity and privacy risks. A single incident can trigger liability claims, regulatory obligations, reputational harm, and insurance challenges. Yet many firms underestimate how contracts, insurance, and internal practices intersect during a breach. This program offers legal and insurance perspectives on cyber risk in architecture, examining liability exposure, risky contract provisions, and mitigation strategies. A cyber insurance expert will explain policy responses, coverage gaps, coordination with professional liability, and best practices for aligning insurance with contractual risk and protecting firms from evolving cyber threats. Learning Objectives: Identify key cybersecurity and data privacy risks faced by architecture firms and explain how these risks can impact professional liability and project outcomes. Analyze common contractual provisions to determine which clauses may increase exposure to cyber incidents and propose strategies to mitigate these risks. Evaluate the scope and limitations of cyber insurance policies, including coordination with professional liability coverage, to determine how a policy would respond in a breach scenario. Develop actionable risk management strategies by integrating legal, contractual, and insurance considerations to protect sensitive client and project data.
  • Podcasts
    Art Appraisal and Market Value with David Shapiro
    How do you determine the value of a work of art—and what happens when that valuation impacts taxes, insurance, estate planning, or an artist’s legacy? On this episode of The Legal Canvas, host Caryn Keppler, trust and estates attorney at Offit Kurman, welcomes David Shapiro of David Shapiro Fine Art, a certified member of the Appraisers Association of America specializing in post-war and contemporary art, with accreditation in impressionist and modern art. David shares insights into the art appraisal process, explaining the differences between fair market value, retail replacement value, and marketable cash value. He discusses how appraisers evaluate unique works using comparable sales, provenance, condition, exhibition history, and other factors that influence value. The conversation also explores the role of art advisors in buying and selling artwork, strategies for expanding an artist’s presence in a global market, and the complexities of valuing large collections for estate and tax purposes. David explains how a work’s history and the story behind it can influence its market performance—and why thoughtful planning and organization are essential to preserving an artist’s legacy. In this episode, you’ll learn about: The differences between art appraisal methods and why the type of valuation matters. What collectors need to know about appraisals for insurance, charitable donations, and tax purposes. How provenance, condition, and comparable sales influence an artwork’s value. How art advisors help collectors navigate auctions, negotiate terms, and maximize sale opportunities. Why artists should cultivate relationships and exhibition opportunities across multiple markets. How blockage discounts can affect the valuation of large artist estates. Why documenting an artwork’s history can make a meaningful difference in its market performance. Whether you’re an artist, collector, estate planning professional, or art enthusiast, this episode offers valuable insight into the intersection of art, valuation, and legacy planning.  Listen to The Legal Canvas for more conversations exploring the intersection of estate planning, taxes, and the creative arts.
  • Events
    The 2026 Economic, Tax, and Accounting Updates
    We are looking forward to the Mid-Atlantic CFO Roundtable's next event on November 13, 2026. This is a program with topics built for Finance Executives. We are extremely fortunate to have three excellent speakers: Dr. Daraius Irani, Vice President of Business and Public Engagement at Towson University; Mike Stankus, Tax Office Managing Principal at BDO; and Daniel Wahlberg, Managing Partner of Acclare Solutions. The economy is rapidly changing with various factors driving it. The November 3rd midterm elections may also have an impact. Our three expert presenters will discuss the ramifications of the election, and the current year updates to GAAP financial reporting and Federal and State income taxes. Please join us for what will surely be an informative and timely discussion. Meet Our Speakers: Daraius Irani, Ph.D. • Towson University Vice President, Business & Public Engagement Dr. Daraius Irani serves as Vice President of Business and Public Engagement at Towson University as well as the chief economist for the Regional Economic Studies Institute (RESI) at Towson University, a policy group providing economic, fiscal impact, and policy analysis to public and private entities.  Dr. Irani is often called upon to provide economic presentations to organizations across Maryland. He has appeared on numerous television programs and in local and regional print media. Dr. Irani holds a Ph.D. in economics from University of California, Santa Barbara. Dan Wahlberg • Acclare Solutions Managing Partner With over 28 years of experience, Dan Wahlberg is a recognized leader in audit and assurance for the Mid-Atlantic’s middle market business community. As a licensed CPA in Maryland and Virginia, Dan has led assurance practices at top regional firms, including serving as Baltimore Audit Managing Partner and Assurance Practice Leader at BDO USA in Baltimore and as Partner and member of the Management Committee at Hertzbach & Company P.A which merged into BDO in 2020. His expertise centers on delivering clarity, strategic guidance, and proactive solutions to middle-market businesses across Baltimore and beyond. His entrepreneurial spirit has led him to begin a new CPA firm this year with four other CPAs serving the business community. Dan holds a Bachelor of Science in Accounting from Rutgers University and began his career at PWC in New York. He is also deeply engaged in the community, previously serving as President of ACG Maryland and current Board member and as Audit Committee Member for The Associated: Jewish Federation of Baltimore.  Mike Stankus • BDO USA LLP Tax Office Managing Principal Mike Stankus is the Tax Office Managing Principal for the firm’s Baltimore office. He has more than 16 years of experience providing tax planning and preparation and management advisory services for his clients. Mike focuses on advising privately held businesses and their owners on effective growth and tax strategies. He also performs various engagements for mergers and acquisitions and complex cost accounting projects and projections. In addition, he represents various government contracting clients before the DCAA and assists with FAR compliance. Mike’s areas of concentration include working with government contractors, professional service firms, construction companies, and homebuilders.